Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor

Wienen, Frederik; Nilson, Robin; Allmendinger, Ellen; Graumann, David; Fiedler, Erik; Bosse-Doenecke, Eva; Kochanek, Stefan; Krutzke, Lea

doi:10.1016/j.bioadv.2022.213208

Cited by 6 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because Ub does not have post-translational modifications, it may be easily obtained in a recombinant form in bacteria [ 167 ]; its poor half-life in circulation, however, might be one of its drawbacks—this could need linking to other proteins, like Fc or BSA [ 167 ]. To overcome these restrictions, Affilin ® has also been employed in combination with antibodies and fab in various forms as a bispecific molecule and pair to adenoviral vectors [ 168 , 169 ]. Multiple targets focused on cancer therapy have been evaluated; however, their in vivo evaluation is still necessary.…”

Section: Biopharmaceutical Use Of Ubmentioning

confidence: 99%

Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb)

Mendoza-Salazar,

Fragozo,

González-Martínez

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Monomeric ubiquitin (Ub) is a 76-amino-acid highly conserved protein found in eukaryotes. The biological activity of Ub first described in the 1970s was extracellular, but it quickly gained relevance due to its intracellular role, i.e., post-translational modification of intracellular proteins (ubiquitination) that regulate numerous eukaryotic cellular processes. In the following years, the extracellular role of Ub was relegated to the background, until a correlation between higher survival rate and increased serum Ub concentrations in patients with sepsis and burns was observed. Although the mechanism of action (MoA) of extracellular ubiquitin (eUb) is not yet well understood, further studies have shown that it may ameliorate the inflammatory response in tissue injury and multiple sclerosis diseases. These observations, compounded with the high stability and low immunogenicity of eUb due to its high conservation in eukaryotes, have made this small protein a relevant candidate for biotherapeutic development. Here, we review the in vitro and in vivo effects of eUb on immunologic, cardiovascular, and nervous systems, and discuss the potential MoAs of eUb as an anti-inflammatory, antimicrobial, and cardio- and brain-protective agent.

show abstract

Section: Biopharmaceutical Use Of Ubmentioning

confidence: 99%

Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb)

Mendoza-Salazar,

Fragozo,

González-Martínez

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Because Ub does not have post-translational modifications it may be easily obtained in a recombinant form in bacteria [161], its poor half-life in circulation, however, might be one of its drawbacks, this could need linking to other proteins, like Fc or BSA [161]. To get over these restrictions, Affilin ® has also been employed in combination with antibodies and Fab in various forms as a bispecific molecule and pair to adenoviral vectors [162,163]. Multiple targets focused on cancer therapy have been evaluated; however, it's in vivo evaluation is still necessary.…”

Section: Use Of Ubiquitin As Scaffoldsmentioning

confidence: 99%

Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb)

Mendoza-Salazar,

Fragozo,

González-Martínez

et al. 2024

Preprint

View full text Add to dashboard Cite

Monomeric Ubiquitin (Ub) is a 76-amino acid highly conserved protein found in eukaryotes. The first described biological activity of Ub in the 1970s was extracellular, but it quickly gained relevance due to its intracellular role, i.e., post-translational modification of intracellular proteins (ubiquitination) that regulate numerous eukaryotic cellular processes. In the following years, the extracellular role of Ub was relegated to the background, until a correlation between higher survival rate and increased serum Ub concentrations in patients with sepsis and burns was observed. Although the mechanism of action (MoA) of extracellular ubiquitin (eUb) is not yet well understood, further studies have shown that it may ameliorate the inflammatory response in tissue injury and multiple sclerosis diseases. These observations compounded with the high stability and low immunogenicity of eUb due to its high conservation in eukaryotes have made this small protein a relevant candidate for biotherapeutic development. Here, we review the in vitro and in vivo effects of eUb on immunologic, cardiovascular, and nervous systems, and discuss the potential MoAs of eUb as an anti-inflammatory, antimicrobial, cardio- and brain-protective agent.

show abstract

Nanoengineering‐armed oncolytic viruses drive antitumor response: progress and challenges

Zhang,

Shi,

Shen

et al. 2024

MedComm

View full text Add to dashboard Cite

Oncolytic viruses (OVs) have emerged as a powerful tool in cancer therapy. Characterized with the unique abilities to selectively target and lyse tumor cells, OVs can expedite the induction of cell death, thereby facilitating effective tumor eradication. Nanoengineering‐derived OVs overcome traditional OV therapy limitations by enhancing the stability of viral circulation, and tumor targeting, promising improved clinical safety and efficacy and so on. This review provides a comprehensive analysis of the multifaceted mechanisms through which engineered OVs can suppress tumor progression. It initiates with a concise delineation on the fundamental attributes of existing OVs, followed by the exploration of their mechanisms of the antitumor response. Amid rapid advancements in nanomedicine, this review presents an extensive overview of the latest developments in the synergy between nanomaterials, nanotechnologies, and OVs, highlighting the unique characteristics and properties of the nanomaterials employed and their potential to spur innovation in novel virus design. Additionally, it delves into the current challenges in this emerging field and proposes strategies to overcome these obstacles, aiming to spur innovation in the design and application of next‐generation OVs.

show abstract

Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor

Cited by 6 publications

References 47 publications

Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb)

Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb)

Almost 50 Years of Monomeric Extracellular Ubiquitin (eUb)

Nanoengineering‐armed oncolytic viruses drive antitumor response: progress and challenges

Contact Info

Product

Resources

About